Millions of individuals worldwide who endure chronic knee pain from osteoarthritis may soon have access to a groundbreaking treatment option that requires no surgery and provides lasting relief through a single injection.
Genicular artery embolization, known as GAE, represents an emerging minimally invasive treatment that specifically targets the abnormal blood vessels responsible for driving inflammation and pain in osteoarthritic knees. The procedure involves a radiologist guiding a thin catheter directly to each affected vessel and injecting tiny particles to block it, thereby calming inflammation and reducing pain without surgical intervention.
The injection utilizes rapidly resorbable, gelatin-based microspheres engineered to dissolve within hours. This innovative approach addresses a fundamental problem in osteoarthritic knees, where abnormal vessels accumulate around the joint and perpetuate a cycle of inflammation and discomfort.
"For the right patient, it can mean lasting relief from a single, minimally invasive procedure—a meaningful new option between injections and joint replacement," said Dr. Florian Fleckenstein, who led a major trial into GAE from his research hub in Berlin, Germany, speaking to Good News Network. "By reducing both inflammation and pain, GAE with resorbable microspheres may be the first procedure that alters the course of the disease, slowing its progression."
The significance of this development cannot be overstated. Osteoarthritis, the most common form of arthritis, causes inflammation, stiffness, reduced mobility, and sensory nerve pain. According to the World Health Organization, knee osteoarthritis affects more than 365 million adults worldwide and ranks among the leading contributors to disability.
Dr. Fleckenstein explained to Good News Network that many patients face a significant treatment gap. For numerous individuals, joint replacement surgery is not a viable option due to medical or personal reasons. "GAE is a whole new treatment regimen that targets abnormal hypervascularity around the joint and, in turn, modulates the pathological neurovascular environment," he stated.
The comprehensive study led by Dr. Fleckenstein enrolled 114 women and 80 men with an average age of 69 years. All participants suffered from osteoarthritis-related knee pain that had not responded to at least three months of conventional treatment, including physiotherapy, anti-inflammatory drugs, and intra-articular injections.
"We believe these results carry real weight because they come from real-world data. With this broad, inclusive study design, our participants are exactly the patients that physicians encounter every day in their practices," Dr. Fleckenstein told Good News Network.
All participants underwent GAE with the resorbable microspheres between July and November 2024. Approximately one in four participants underwent two GAE procedures for bilateral knee osteoarthritis, with the second procedure conducted within four weeks of the first. In total, the patients underwent 239 GAE procedures using the resorbable microspheres.
The safety profile of the procedure proved exceptional. All procedures were technically successful with no moderate or severe adverse events reported. Only mild, self-limited reactions occurred in 6.7 percent of the study group. An orthopedic surgeon conducted a six-month follow-up examination in person for all participants.
The results demonstrated substantial improvements across multiple measures. The study cohort experienced a significant drop in pain levels and a significant increase in function, including sports and recreation activities and daily living tasks. "Most importantly, their quality of life significantly increased," Dr. Fleckenstein said, according to Good News Network.
According to findings published in the journal Radiology, pain scores fell quickly and continued improving over time. Osteoarthritis-related symptoms also showed marked improvement. At the 12-month follow-up point, 80 percent of the participants achieved improvements exceeding the minimum clinically important difference, a threshold that indicates meaningful benefit to patients.
"Our study demonstrates that GAE using rapidly resorbable gelatin-based microspheres is a safe, minimally invasive therapy that provides meaningful pain relief and functional improvement in participants with osteoarthritis-related knee symptoms for at least 12 months," Dr. Fleckenstein stated, speaking to Good News Network.
The mechanism behind the treatment's success lies in its ability to normalize vessel structure. "By embolizing the pathological vessels, we're able to normalize the vessel structure—and, in turn, the neuronal structure of the knee," Dr. Fleckenstein explained to Good News Network.
Dr. Fleckenstein emphasized the strength of the evidence supporting this treatment approach. With almost 200 patients, the study represents the largest body of evidence yet for GAE using rapidly resorbable microspheres. "This lets us speak about safety and efficacy with real confidence," he told Good News Network.
For the millions of individuals who struggle with the daily burden of knee osteoarthritis, this procedure offers a promising middle ground between temporary relief from injections and the major commitment of joint replacement surgery. As the medical community continues to evaluate and refine this technique, it may become an increasingly important tool in managing one of the most common and debilitating conditions affecting adults worldwide.